Abstracts tagged "Psoriatic arthritis"

Abstract Number: 2488 • 2019 ACR/ARP Annual Meeting
MDA Versus DAPSA: Applicability in a Real World
rafaela Gonçalves¹, Lays Martins ², henrique mariz ¹, marina brito ³, georgia pereira ³, andrea dantas ³ and Angela Duarte ², ¹clinical hospital of federal university of pernambuco, recife, Pernambuco, Brazil, ²Universidade Federal de Pernambuco, Recife, Brazil, ³clinical hospital of federal university of pernambuco, recife, Brazil
Background/Purpose: Background/Purpose: Psoriatic arthritis (PsA) is a progressive, chronic, and potentially irreversible inflammatory disorder. Systematic clinical follow-up of PsA patients is necessary to maintain and…
Abstract Number: 2511 • 2019 ACR/ARP Annual Meeting
What Influences Patients’ Opinion of Remission and Low Disease Activity in Psoriatic Arthritis? Principal Component Analysis of an International Study
Laura Coates¹, Danielle Robinson ², Ana-Maria Orbai ³, Uta Kiltz ⁴, Ying-Ying Leung ⁵, Penelope Palominos ⁶, Juan Cañete ⁷, Rossana Scrivo ⁸, Andra Balanescu ⁹, Emmanuelle Dernis ¹⁰, Sandra Talli ¹¹, Adeline Ruyssen-Witrand ¹², Lihi Eder ¹³, Maarten de Wit ¹⁴, Josef Smolen ¹⁵, Ennio Lubrano ¹⁶ and Laure Gossec ¹⁷, ¹University of Oxford, Oxford, United Kingdom, ²Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom, ³Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ⁴Rheumazentrum Ruhrgebiet/Ruhr University Bochum, Herne, Germany, Herne, Germany, ⁵Department of Rheumatology and Immunology, Singapore General Hospital,, Singapore, Singapore, ⁶Serviço de Reumatologia, Hospital de Clínicas de Porto Alegre, Universidade Federal do Rio Grande do Sul,, Porto Alegra, Brazil, ⁷Rheumatology Department, Hospital Clínic and IDIBAPS,, Barcelona, Spain, ⁸Rheumatology Unit, Department of Internal Medicine and Medical Specialties, Sapienza Università di Roma,, Rome, Italy, ⁹Sf Maria Hospital, University of Medicine and Pharmacy Carol Davila, Bucharest, Romania, ¹⁰Rheumatology Department, Le Mans Central Hospital, Le Mans, France, ¹¹Rheumatology Department, East-Tallinn Central Hospital, Tallinn, Estonia, ¹²Rheumatology Unit, Toulouse university Hospital, UMR 1027, Inserm, Université Paul Sabatier Toulouse III, Toulouse, France, ¹³Women’s College Hospital and the Department of Medicine, University of Toronto, Toronto, Canada, ¹⁴Department of Medical Humanities, Amsterdam Public Health (APH), Amsterdam University Medical Centre, Amsterdam, Netherlands, ¹⁵Medical University of Vienna, Vienna, Austria, ¹⁶15. Academic Rheumatology Unit, Dipartimento di Medicina e Scienze della Salute ’Vincenzo Tiberio’, University of Molise, Campobasso, Italy, ¹⁷Sorbonne Université and Pitié Salpêtrière Hospital, Paris, France
Background/Purpose: In psoriatic arthritis (PsA), the objective of treatment is remission or low disease activity (LDA), but there is little research into patients’ perception of…
Abstract Number: 2880 • 2019 ACR/ARP Annual Meeting
Secukinumab Improves Axial Manifestations in Patients with Psoriatic Arthritis and Inadequate Response to NSAIDs: Primary Analysis of Phase 3 Trial
Xenofon Baraliakos¹, Laura Coates ², Laure Gossec ³, Slawomir Jeka ⁴, Antonio Mera ⁵, Barbara Schulz ⁶, Michael Rissler ⁶, Ayan Das Gupta ⁷, Chiara Perella ⁶ and Effie Pournara ⁸, ¹Rheumatology Department, Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Bochum, Germany, ²University of Oxford, Oxford, United Kingdom, ³Sorbonne Université and Hôpital Pitié-Salpêtrière, Paris, France, ⁴University Hospital Bydgoszcz no 2, CM UMK, Bydgoszcz, Poland, ⁵Division of Rheumatology, Instituto de Investigación Sanitaria-Hospital Clinico Universitario de Santiago, Santiago de Compostela, Spain, Santiago de Compostela, Spain, ⁶Novartis Pharma AG, Basel, Switzerland, ⁷Novartis Healthcare Pvt Ltd, Hyderabad, India, ⁸Novartis Pharma AG, Basel, Basel-Stadt, Switzerland
Background/Purpose: Secukinumab (SEC) has provided significant and sustained improvement in the signs and symptoms of active psoriatic arthritis (PsA) and ankylosing spondylitis1. Evidence is limited…
Abstract Number: 291 • 2019 ACR/ARP Annual Meeting
Factors Explaining Patient Perspective in Psoriasis and Psoriatic Arthritis: The Role of Inflammation and Structural Damage Detected by Ultrasound
Tania Gudu¹, Ilaria Padovano ¹, Hélène Gouze ², François Vidal ¹, Emmanuel Mahé ³, Leire Lara Gonzalez ⁴, Alexis Guyot ⁴, Philippe Saiag ⁴, Isabelle Bourgault Villada ⁴, Sophie Ruel-Gagné ¹, Gilles Hayem ¹, Félicie Costantino ⁵, Maxime Breban ⁶ and Maria-Antonietta D’Agostino ⁷, ¹Rheumatology Department, APHP, Ambroise Paré Hospital, Boulogne Billancourt, France, ²Rheumatology Department, APHP, Ambroise Paré Hospital, Bolougne Billancourt, France, ³Dermatology Department, Victor Dupouy Hospital, Argenteuil, France, ⁴Dermatology Department, Ambroise Paré Hospital, Boulogne Billancourt, France, ⁵UMR1173, INSERM/Versailles-Saint Quentin University, France Ambroise Paré Hospital (AP-HP) Department of Rheumatology, Boulogne-Billancourt, France, Boulogne Billancourt, France, ⁶UMR1173, INSERM/Versailles-Saint Quentin University, France Ambroise Paré Hospital (AP-HP) Department of Rheumatology, Boulogne-Billancourt, France, Boulogne Billancourt, ⁷Department of Rheumatology, APHP, Hôpital Ambroise Paré, Paris, France
Background/Purpose: Patient reported outcomes (PROs) reflect patients’ opinion on disease activity, impact of disease, quality of life (QoL), disability and are essential in the assessment…
Abstract Number: 1009 • 2019 ACR/ARP Annual Meeting
PDE4 Inhibition Could Improve Endothelial and Adipose Tissue Dysfunction Associated with Psoriatic Arthritis, Key Processes in Cardiovascular Disease
Ivan Arias de la Rosa¹, Carmen Torres-Granados ¹, Maria del Carmen Abalos-Aguilera ², Ignacio Gomez-Garcia ², Rocio Guzman-Ruiz ³, Maria del Mar Malagon ³, Carlos Perez-Sanchez ⁴, Alejandra Patiño-Trives ², Maria Luque-Tevar ², Alejandro Ibañez-Costa ², Alejandro Escudero ⁵, Eduardo Collantes-Estevez ¹, Chary Lopez-Pedrera ², Maria Dolores Lopez-Montilla ² and Nuria Barbarroja ³, ¹University of Cordoba/IMIBIC/Reina Sofia Hospital, Cordoba, Spain, ²IMIBIC/Reina Sofia Hospital/University of Cordoba, Cordoba, Spain, ³University of Cordoba/IMIBIC/Reina Sofia Hospital and CIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III, Cordoba, Spain, ⁴Rheumatology service, IMIBIC/Reina Sofia Hospital/University of Cordoba, Cordoba, Spain, Cordoba, Spain, ⁵IMIBIC/Reina Sofia Hospital/University of Cordoba, Córdoba, Spain
Background/Purpose: Psoriatic arthritis (PsA) is the rheumatic disease most associated with metabolic disorders, including obesity and metabolic syndrome, where inflammation is a determinant key factor,…
Abstract Number: 1211 • 2019 ACR/ARP Annual Meeting
Improving Exercise Counselling of Patients with Inflammatory Arthritis: A Quality Improvement Project
Anwar Albasri ¹, Tariq Al-Araimi ¹, Stephanie Gottheil¹, Lauren King ¹, Sahil Koppikar ², Justin Shamis ¹, Shirley Lake ³ and Gakhal Natasha ¹, ¹University of Toronto, Toronto, Canada, ²University of Toronto, Markham, ON, Canada, ³Division of Rheumatology, Sunnybrook Hospital, Toronto, ON, Canada
Background/Purpose: Regular aerobic exercise has been shown to improve inflammatory arthritis (IA) symptoms and may reduce the risk of cardiovascular events observed in these patients.…
Abstract Number: 1517 • 2019 ACR/ARP Annual Meeting
Effect of Long-Term Treatment with Secukinumab on Cardio-Metabolic Profile in Patients with Active Ankylosing Spondylitis and Psoriatic Arthritis: Pooled 3 Year Analysis
Iain McInnes¹, Dafna Gladman ², Atul Deodhar ³, Corinne Miceli-Richard ⁴, Peter Nash ⁵, Naveed Sattar ⁶, Nehal Mehta ⁷, Darren Asquith ⁸, Jianyuan Wang ⁹, Hanno Richards ⁹, Luminita Pricop ¹⁰ and Abhijit Shete ⁹, ¹Institute of Infection, Immunity & Inflammation, University of Glasgow, Glasgow, United Kingdom, ²Toronto Western Hospital, Toronto, Canada, Toronto, ON, Canada, ³Oregon Health & Science University, Portland, OR, ⁴Paris Descartes University, Department of Rheumatology - Hôpital Cochin, Assistance Publique - Hôpitaux de Paris, Paris, France, ⁵University of Queensland, Brisbane, Queensland, Australia, ⁶Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, United Kingdom, ⁷National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD, USA, Bethesda, MD, ⁸Novartis Pharmaceuticals UK Limited, Surrey, United Kingdom, ⁹Novartis Pharma AG, Basel, Switzerland, ¹⁰Novartis Pharmaceuticals Corporation, East Hanover, NJ
Background/Purpose: Systemic inflammation may influence cardio-metabolic profiles and increases the risk of CV disorders in ankylosing spondylitis (AS) and psoriatic arthritis (PsA) patients (pts)1. Treatment…
Abstract Number: 1777 • 2019 ACR/ARP Annual Meeting
The Deubiquitinase TRABID Is a Potential Therapeutic Target in Spondyloarthritis
Daniele Mauro¹, Federica Macaluso ², Alessandra Nerviani ³, Marie-Astrid Boutet ³, Aroldo Rizzo ⁴, Riccardo Alessandro ², Giuliana Guggino ², Costantino Pitzalis ³ and Francesco Ciccia ⁵, ¹Centre for Experimental Medicine & Rheumatology, Queen Mary University of London, London, England, United Kingdom, ²University of Palermo, Italy, Palermo, Italy, ³Centre for Experimental Medicine & Rheumatology, Queen Mary University of London, London, United Kingdom, ⁴Pathology Unit, Azienda Ospedaliera Ospedali Riuniti Villa Sofia Cervello, Palermo, Italy., Palermo, Italy, ⁵University of Campania L. Vanvitelli, Naples, Italy
Background/Purpose: Interleukin 12 (IL-12) and 23 (IL-23) may play a pivotal role in the pathogenesis of inflammatory diseases, including Spondyloarthritis (SpA). In mice, the deubiquitinase…
Abstract Number: 2448 • 2019 ACR/ARP Annual Meeting
Factors Associated with Discordance Between Patient and Rheumatologist Assessment of Disease Activity in Psoriatic Arthritis Considered in Remission
Marie Moly¹, Cédric Lukas ², Jacques Morel ¹, Bernard Combe ³ and Gaël Mouterde ⁴, ¹CHU Montpellier, Montpellier, France, ²Rheumatology department, CHU Montpellier, Univ Montpellier, Montpellier, France, ³CHU Montpellier, Montpellier University, Montpellier, France, ⁴CHU Montpellier and Univ Montpellier, Montpellier, France
Background/Purpose: Assessment of disease activity in psoriatic arthritis (PsA) requires evaluation of multiple aspects and can be difficult. Perception of disease activity by patient and…
Abstract Number: 2468 • 2019 ACR/ARP Annual Meeting
JAK-STAT Signaling System in Pannus Formation of Psoriatic Arthritis: A Therapeutic Target
Siba Raychaudhuri¹ and Smritikana Raychaudhuri ², ¹UC Davis School of Medicine, Sacramento, CA, ²UC Davis School of Medicine, Davis, CA
Background/Purpose: Psoriatic arthritis (PsA) involves inflammation of the joint synovium where synovial cells (FLS) are the target for T cell activated cytokines for pannus formation.…
Abstract Number: 2489 • 2019 ACR/ARP Annual Meeting
Differences in Clinical Characteristics, Quality of Life, Disability, and Work Productivity in Psoriatic Arthritis Patients by Gender: Findings from a Cross-sectional Survey in the US and Europe
Laure Gossec¹, Jessica Walsh ², Kaleb Michaud ³, Steve Peterson ⁴, Elizabeth Holdsworth ⁵, Chetan Karyekar ⁴, Nicola Booth ⁶, Jessalyn Kemp ⁷, Soumya Chakravarty ⁸, Shelly Kafka ⁹ and Alexis Ogdie ¹⁰, ¹Sorbonne Université and Hôpital Pitié-Salpêtrière, Paris, France, ²Division of Rheumatology, University of Utah, Salt Lake City, UT, ³University of Nebraska Medical Center, Omaha, NE, ⁴Janssen Global Services, LLC, Horsham, PA, ⁵Adelphi Real World, Manchester, England, United Kingdom, ⁶Adelphi Real World, Bollington, United Kingdom, ⁷Adelphi Real World, Manchester, United Kingdom, ⁸Janssen Scientific Affairs, LLC; Drexel University College of Medicine, Horsham; Philadelphia, PA, ⁹Janssen Scientific Affairs, LLC, Horsham, PA, ¹⁰Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA
Background/Purpose: Psoriatic arthritis (PsA) prevalence is equal in men and women, though gender may play a role in driving mechanisms of PsA leading to differences…
Abstract Number: 2512 • 2019 ACR/ARP Annual Meeting
A Qualitative Study of Clinicians’ Perspectives on Barriers to Implementation of Treat to Target in Psoriatic Arthritis
Julie Taylor ¹, Laura Coates² and Emma Dures ¹, ¹Department of Nursing and Midwifery, University of the West of England, Bristol and Academic Rheumatology, University Hospitals NHS Trust, Bristol, England, United Kingdom, ²University of Oxford, Oxford, United Kingdom
Background/Purpose: European League Against Rheumatism Treatment recommendations support implementing a treat-to-target (T2T) approach in psoriatic arthritis (PsA) based on the findings of the TICOPA trial.…
Abstract Number: 421 • 2019 ACR/ARP Annual Meeting
An Examination of Patient-Reported Outcomes Data from a Randomized Trial Examining Etanercept and Methotrexate as Monotherapy or in Combination in Patients with Psoriatic Arthritis
Vibeke Strand¹, Philip Mease ², Ervant Maksabedian ³, Bradley Stolshek ³, Lyrica Liu ³, David Collier ³, Gregory Kricorian ³ and Joseph Merola ⁴, ¹Division of Immunology/Rheumatology, Stanford University, Stanford, CA, ²Swedish Medical Center/Providence St Joseph Health, and University of Washington, Seattle, WA, ³Amgen Inc., Thousand Oaks, CA, ⁴Harvard Medical School, Brigham and Women’s Hospital, Boston, MA
Background/Purpose: Health-related quality of life is impacted in patients (pts) with psoriatic arthritis (PsA). Patient-reported outcomes (PROs) are an important means of measuring treatment improvements…
Abstract Number: 1011 • 2019 ACR/ARP Annual Meeting
Single Cell RNA Sequencing of Patients with Psoriatic Disease
Rohan Machhar¹, Kun Liang ², Remy Pollock ¹ and Dafna Gladman ³, ¹Krembil Research Institute, University Health Network, Toronto, Canada, ²University of Waterloo, Waterloo, ON, Canada, ³Krembil Research Institute, U of Toronto, Toronto, ON, Canada
Background/Purpose: Delayed diagnosis of psoriatic arthritis (PsA) can lead to poor clinical outcomes. A large proportion of PsA patients remain undiagnosed due to a lack…
Abstract Number: 1431 • 2019 ACR/ARP Annual Meeting
Real-Life Golimumab Persistence in Patients with Chronic Inflammatory Rheumatic Disease: Results of the GO PRACTICE Study
René-Marc Flipo¹, Florence Tubach ², Jean Ouaniche ³, Philippe Goupille ⁴, Eric Lespessailles ⁵, Najat Gouyette ⁶, Naoual Harid ⁷, Saannya Sequiera ⁸, Philippe Bertin ⁹ and Bruno Fautrel ¹⁰, ¹Roger Salengro University-Hospital, Lille , France, Lille, France, ²Pitié Salpétrière University-Hospital, Paris, Ile-de-France, France, ³Private Practice , Toulon, France, Toulon, France, ⁴Tours University-Hospital, Tours, France, Tours, France, ⁵Orléans Regional Hospitals, Orléans ,France, Orléans, France, ⁶MSD France, Courbevoie ,France, Courbevoie, Ile-de-France, France, ⁷MSD France, Courbevoie, France, Courbevoie, Ile-de-France, France, ⁸ClinSearch ,Malakoff, France, Malakoff, Ile-de-France, France, ⁹Limoges University-Hospital , Limoges, France, Limoges, France, ¹⁰Pitié-Salpêtrière Hospital, Department of Rheumatology, AP-HP, Sorbonne University, UPMC university, Paris, Ile-de-France, France
Background/Purpose: The GO PRACTICE study was initiated following a demand by the French Health Authorities for long-term data on the real-life use of golimumab (GLM)…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].